The impact of intra-clonal heterogeneity on the treatment of multiple myeloma

British Journal of Haematology

Volumn 165, Issue 4, 2014, Pages 441-454

  Brioli, Annamaria ^a,b   Melchor, Lorenzo ^a   Cavo, Michele ^b   Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Clonal heterogeneity; Genetics; Multiple myeloma; Sequential treatment; Therapy

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; THALIDOMIDE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER RECURRENCE; CONSOLIDATION CHEMOTHERAPY; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HIGH THROUGHPUT SEQUENCING; HUMAN; INDUCTION CHEMOTHERAPY; MAINTENANCE THERAPY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SINGLE CELL ANALYSIS;

CLONAL HETEROGENEITY; GENETICS; MULTIPLE MYELOMA; SEQUENTIAL TREATMENT; THERAPY;

ANTINEOPLASTIC AGENTS; CELL LINEAGE; CLONE CELLS; CONSOLIDATION CHEMOTHERAPY; DISEASE MANAGEMENT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; EVOLUTION, MOLECULAR; HUMANS; MAINTENANCE CHEMOTHERAPY; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; MUTATION; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PLASMACYTOMA; REMISSION INDUCTION; SELECTION, GENETIC; TREATMENT OUTCOME;

EID: 84899485783     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12805     Document Type: Review

References (111)

1. Anderson, K.C. (2011) New insights into therapeutic targets in myeloma. Hematology American Society of Hematology Education Program, 2011, 184-190.
2. Anderson, K., Lutz, C., van Delft, F.W., Bateman, C.M., Guo, Y., Colman, S.M., Kempski, H., Moorman, A.V., Titley, I., Swansbury, J., Kearney, L., Enver, T. & Greaves, M. (2011) Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature, 469, 356-361.
3. Andrulis, M., Lehners, N., Capper, D., Penzel, R., Heining, C., Huellein, J., Zenz, T., von Deimling, A., Schirmacher, P., Ho, A.D., Goldschmidt, H., Neben, K. & Raab, M.S. (2013) Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discovery, 3, 862-869.
4. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine, 335, 91-97.
5. Attal, M., Harousseau, J.L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Yakoub Agha, I., Bourhis, J.H., Garderet, L., Pegourie, B., Dumontet, C., Renaud, M., Voillat, L., Berthou, C., Marit, G., Monconduit, M., Caillot, D., Grobois, B., Avet-Loiseau, H., Moreau, P. & Facon, T. (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood, 108, 3289-3294.
6. Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A.M., Hulin, C., Benboubker, L., Garderet, L., Decaux, O., Leyvraz, S., Vekemans, M.C., Voillat, L., Michallet, M., Pegourie, B., Dumontet, C., Roussel, M., Leleu, X., Mathiot, C., Payen, C., Avet-Loiseau, H. & Harousseau, J.L. (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 366, 1782-1791.
7. Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Facon, T., Hulin, C., Moreau, P., Mathiot, C., Roussel, M., Payen, C., Olivier, P. & Avet-Loiseau, H. (2013) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005-02 trial. Blood, 122, 406.
8. Bardelli, A., Cahill, D.P., Lederer, G., Speicher, M.R., Kinzler, K.W., Vogelstein, B. & Lengauer, C. (2001) Carcinogen-specific induction of genetic instability. Proceedings of the National Academy of Sciences of the United States of America, 98, 5770-5775.
9. Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B. & Crowley, J. (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93, 55-65.
10. Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M. & Crowley, J. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. New England Journal of Medicine, 354, 1021-1030.
11. Barlogie, B., Anaissie, E., van Rhee, F., Haessler, J., Hollmig, K., Pineda-Roman, M., Cottler-Fox, M., Mohiuddin, A., Alsayed, Y., Tricot, G., Bolejack, V., Zangari, M., Epstein, J., Petty, N., Steward, D., Jenkins, B., Gurley, J., Sullivan, E., Crowley, J. & Shaughnessy, J.D. Jr (2007) Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. British Journal of Haematology, 138, 176-185.
12. Barlogie, B., Anaissie, E., Haessler, J., van Rhee, F., Pineda-Roman, M., Hollmig, K., Alsayed, Y., Epstein, J., Shaughnessy, J.D. & Crowley, J. (2008) Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer, 113, 355-359.
13. Barlogie, B., Attal, M., Crowley, J., van Rhee, F., Szymonifka, J., Moreau, P., Durie, B.G. & Harousseau, J.L. (2010) Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. Journal of Clinical Oncology, 28, 1209-1214.
14. Bergsagel, P.L., Kuehl, W.M., Zhan, F., Sawyer, J., Barlogie, B. & Shaughnessy, J. Jr (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood, 106, 296-303.
15. Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K. & Hirth, P. (2012) Vemurafenib: the first drug approved for BRAF-mutant cancer. Nature Reviews Drug Discovery, 11, 873-886.
16. Bolli, N., Avet-Loiseau, H., Wedge, D.C., Van Loo, P., Alexandrov, L.B., Martincorena, I., Dawson, K.J., Iorio, F., Nik-Zainal, S., Bignell, G.R., Hinton, J.W., Li, Y., Tubio, J.M., McLaren, S., O' Meara, S., Butler, A.P., Teague, J.W., Mudie, L., Anderson, E., Rashid, N., Tai, Y.T., Shammas, M.A., Sperling, A.S., Fulciniti, M., Richardson, P.G., Parmigiani, G., Magrangeas, F., Minvielle, S., Moreau, P., Attal, M., Facon, T., Futreal, P.A., Anderson, K.C., Campbell, P.J. & Munshi, N.C. (2014) Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nature Communications, 5, 2997. doi: 10.1038/ncomms3997
17. Brioli, A., Boyd, K.D., Kaiser, M.F., Pawlyn, C., Wu, P., Gregory, W.M., Owen, R., Ross, F.M., Jackson, G.H., Cavo, M., Davies, F.E. & Morgan, G.J. (2013a) Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy. British Journal of Haematology, 161, 291-294.
18. Brioli, A., Davies, F.E., Gregory, W.M., Hinsley, S., Marshall, S., Pawlyn, C., Cavo, M., Jackson, G.H., Russell, N. & Morgan, G.J. (2013b) Low rate of second primary malignancies (SPMs) in newly diagnosed multiple myeloma (MM) patients treated with lenalidomide: first results from the MRC MM XI trial (18th Congress of the European Hematology Association, Stockholm, Sweden, June 13-16, 2013). Haematologica, 98, 104 (P242).
19. Brioli, A., Kaiser, M.F., Pawlyn, C., Wu, P., Gregory, W.M., Owen, R., Ross, F.M., Jackson, G.H., Cavo, M., Davies, F.E. & Morgan, G.J. (2013c) Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. Leukemia & Lymphoma, 54, 1975-1981.
20. Cahill, D.P., Kinzler, K.W., Vogelstein, B. & Lengauer, C. (1999) Genetic instability and darwinian selection in tumours. Trends in Cell Biology, 9, M57-M60.
21. Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., Narni, F., Carubelli, A., Masini, L., Catalano, L., Fiacchini, M., de Vivo, A., Gozzetti, A., Lazzaro, A., Tura, S. & Baccarani, M. (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study. Journal of Clinical Oncology, 25, 2434-2441.
22. Cavo, M., Di Raimondo, F., Zamagni, E., Patriarca, F., Tacchetti, P., Casulli, A.F., Volpe, S., Perrone, G., Ledda, A., Ceccolini, M., Califano, C., Bigazzi, C., Offidani, M., Stefani, P., Ballerini, F., Fiacchini, M., de Vivo, A., Brioli, A., Tosi, P. & Baccarani, M. (2009) Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. Journal of Clinical Oncology, 27, 5001-5007.
23. Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M.T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., Offidani, M., Corradini, P., Narni, F., Spadano, A., Pescosta, N., Deliliers, G.L., Ledda, A., Cellini, C., Caravita, T., Tosi, P. & Baccarani, M. (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet, 376, 2075-2085.
24. Cavo, M., Pantani, L., Petrucci, M.T., Patriarca, F., Zamagni, E., Donnarumma, D., Crippa, C., Boccadoro, M., Perrone, G., Falcone, A., Nozzoli, C., Zambello, R., Masini, L., Furlan, A., Brioli, A., Derudas, D., Ballanti, S., Dessanti, M.L., De Stefano, V., Carella, A.M., Marcatti, M., Nozza, A., Ferrara, F., Callea, V., Califano, C., Pezzi, A., Baraldi, A., Grasso, M., Musto, P. & Palumbo, A. (2012) Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood, 120, 9-19.
25. Chaidos, A., Barnes, C.P., Cowan, G., May, P.C., Melo, V., Hatjiharissi, E., Papaioannou, M., Harrington, H., Doolittle, H., Terpos, E., Dimopoulos, M., Abdalla, S., Yarranton, H., Naresh, K., Foroni, L., Reid, A., Rahemtulla, A., Stumpf, M., Roberts, I. & Karadimitris, A. (2013) Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood, 121, 318-328.
26. Chapman, M.A., Lawrence, M.S., Keats, J.J., Cibulskis, K., Sougnez, C., Schinzel, A.C., Harview, C.L., Brunet, J.P., Ahmann, G.J., Adli, M., Anderson, K.C., Ardlie, K.G., Auclair, D., Baker, A., Bergsagel, P.L., Bernstein, B.E., Drier, Y., Fonseca, R., Gabriel, S.B., Hofmeister, C.C., Jagannath, S., Jakubowiak, A.J., Krishnan, A., Levy, J., Liefeld, T., Lonial, S., Mahan, S., Mfuko, B., Monti, S., Perkins, L.M., Onofrio, R., Pugh, T.J., Rajkumar, S.V., Ramos, A.H., Siegel, D.S., Sivachenko, A., Stewart, A.K., Trudel, S., Vij, R., Voet, D., Winckler, W., Zimmerman, T., Carpten, J., Trent, J., Hahn, W.C., Garraway, L.A., Meyerson, M., Lander, E.S., Getz, G. & Golub, T.R. (2011) Initial genome sequencing and analysis of multiple myeloma. Nature, 471, 467-472.
27. Chauhan, D., Hideshima, T. & Anderson, K.C. (2008) Targeting proteasomes as therapy in multiple myeloma. Advances in Experimental Medicine and Biology, 615, 251-260.
28. Chen, J., Sprouffske, K., Huang, Q. & Maley, C.C. (2011) Solving the puzzle of metastasis: the evolution of cell migration in neoplasms. PLoS One, 6, e17933.
29. Chesi, M. & Bergsagel, P.L. (2011) Many multiple myelomas: making more of the molecular mayhem. Hematology American Society of Hematology Education Program, 2011, 344-353.
30. Chesi, M. & Bergsagel, P.L. (2013) Molecular pathogenesis of multiple myeloma: basic and clinical updates. International Journal of Hematology, 97, 313-323.
31. Chng, W.J., Gonzalez-Paz, N., Price-Troska, T., Jacobus, S., Rajkumar, S.V., Oken, M.M., Kyle, R.A., Henderson, K.J., Van Wier, S., Greipp, P., Van Ness, B. & Fonseca, R. (2008) Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia, 22, 2280-2284.
32. Christensen, J.H., Jensen, P.V., Kristensen, I.B., Abildgaard, N., Lodahl, M. & Rasmussen, T. (2012) Characterization of potential CD138 negative myeloma "stem cells". Haematologica, 97, e18-e20.
33. Corradini, P., Ladetto, M., Inghirami, G., Boccadoro, M. & Pileri, A. (1994) N- and K-ras oncogenes in plasma cell dyscrasias. Leukaemia & Lymphoma, 15, 17-20.
34. Craig, D.W., Liang, W., Venkata, Y., Kurdoglu, A., Aldrich, J., Auclair, D., Allen, K., Harrison, B., Jewell, S., Kidd, P.G., Correll, M., Jagannath, S., Siegel, D.S., Vij, R., Orloff, G., Zimmerman, T.M., Network, M.C., Capone, W., Carpten, J. & Lonial, S. (2013) Interim analysis of the mmrf commpass trial, a longitudinal study in multiple myeloma relating clinical outcomes to genomic and immunophenotypic profiles. Blood, 122, 532.
35. Cuzick, J., Erskine, S., Edelman, D. & Galton, D.A. (1987) A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults. British Journal of Cancer, 55, 523-529.
36. Darwin, C. (1859) On the Origin of Species by Means of Natural Selection. John Murray, London.
37. Davies, F. & Baz, R. (2010) Lenalidomide mode of action: linking bench and clinical findings. Blood Reviews, 24, S13-S19.
38. Dhodapkar, M.V., Sexton, R., Waheed, S., Usmani, S., Papanikolaou, X., Nair, B., Petty, N., Shaughnessy, J.D. Jr, Hoering, A., Crowley, J., Orlowski, R.Z. & Barlogie, B. (2014) Clinical, genomic and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood, 123, 78-85.
39. Dib, A., Gabrea, A., Glebov, O.K., Bergsagel, P.L. & Kuehl, W.M. (2008) Characterization of MYC translocations in multiple myeloma cell lines. Journal of the National Cancer Institute Monographs, 39, 25-31.
40. Dimopoulos, M.A., Moulopoulos, L.A., Maniatis, A. & Alexanian, R. (2000) Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood, 96, 2037-2044.
41. Dimopoulos, M.A., Richardson, P.G., Brandenburg, N., Yu, Z., Weber, D.M., Niesvizky, R. & Morgan, G.J. (2012) A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood, 119, 2764-2767.
42. Ding, L., Ley, T.J., Larson, D.E., Miller, C.A., Koboldt, D.C., Welch, J.S., Ritchey, J.K., Young, M.A., Lamprecht, T., McLellan, M.D., McMichael, J.F., Wallis, J.W., Lu, C., Shen, D., Harris, C.C., Dooling, D.J., Fulton, R.S., Fulton, L.L., Chen, K., Schmidt, H., Kalicki-Veizer, J., Magrini, V.J., Cook, L., McGrath, S.D., Vickery, T.L., Wendl, M.C., Heath, S., Watson, M.A., Link, D.C., Tomasson, M.H., Shannon, W.D., Payton, J.E., Kulkarni, S., Westervelt, P., Walter, M.J., Graubert, T.A., Mardis, E.R., Wilson, R.K. & DiPersio, J.F. (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 481, 506-510.
43. Egan, J.B., Shi, C.-X., Tembe, W., Christoforides, A., Kurdoglu, A., Sinari, S., Middha, S., Asmann, Y., Schmidt, J., Braggio, E., Keats, J.J., Fonseca, R., Bergsagel, P.L., Craig, D.W., Carpten, J.D. & Stewart, A.K. (2012) Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood, 120, 1060-1066.
44. Facon, T., Dimopoulos, M.A., Dispenzieri, A., Catalano, J.V., Belch, A.R., Hulin, C., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N.J., Banos, A., Tiab, M., Delforge, M., Cavenagh, J.D., Geraldes, C., Lee, J.-J., Chen, C.I., Oriol, A., De La Rubia, J., Qiu, L., White, D.J., Binder, D., Anderson, K.C., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C.J., Ervin-Haynes, A. & Benboubker, L. (2013) Initial phase 3 results of the first (frontline investigation of lenalidomide + dexamethasone versus standard thalidomide) Trial (MM-020/IFM 07 01) In newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for stem cell transplantation (SCT). Blood, 122, 2.
45. Fonseca, R., Bailey, R.J., Ahmann, G.J., Rajkumar, S.V., Hoyer, J.D., Lust, J.A., Kyle, R.A., Gertz, M.A., Greipp, P.R. & Dewald, G.W. (2002) Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood, 100, 1417-1424.
46. Fonseca, R., Bergsagel, P.L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, A.K., Morgan, G., Van Ness, B., Chesi, M., Minvielle, S., Neri, A., Barlogie, B., Kuehl, W.M., Liebisch, P., Davies, F., Chen-Kiang, S., Durie, B.G., Carrasco, R., Sezer, O., Reiman, T., Pilarski, L. & Avet-Loiseau, H. (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia, 23, 2210-2221.
47. Gay, F., Cavallo, F., Caravita, T., Cavalli, M., Nagler, A., Montefusco, V., Pogliani, E.M., Buttignol, S., Zamagni, E., Palladino, C., Marcatti, M., Musto, P., Catalano, L., Baraldi, A., Carella, A.M., Cafro, A.M., Siniscalchi, A., Crippa, C., Vallone, L.M., Ciccone, G., Ben Yehuda, D., Di Raimondo, F., Hardan, I., Boccadoro, M. & Palumbo, A. (2013) Maintenance therapy with lenalidomide significantly improved survival of yong newly diagnosed multiple myeloma patients. Blood, 122, 2089.
48. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., Varela, I., Phillimore, B., Begum, S., McDonald, N.Q., Butler, A., Jones, D., Raine, K., Latimer, C., Santos, C.R., Nohadani, M., Eklund, A.C., Spencer-Dene, B., Clark, G., Pickering, L., Stamp, G., Gore, M., Szallasi, Z., Downward, J., Futreal, P.A. & Swanton, C. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine, 366, 883-892.
49. Ghobrial, I.M. (2012) Myeloma as a model for the process of metastasis: implications for therapy. Blood, 120, 20-30.
50. Greaves, M. (2013) Cancer stem cells as 'units of selection'. Evolutionary Applications, 6, 102-108.
51. Greaves, M. & Maley, C.C. (2012) Clonal evolution in cancer. Nature, 481, 306-313.
52. Harousseau, J.L., Attal, M. & Avet-Loiseau, H. (2009) The role of complete response in multiple myeloma. Blood, 114, 3139-3146.
53. Harousseau, J.L., Attal, M., Avet-Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T., Casassus, P., Michallet, M., Maisonneuve, H., Benboubker, L., Maloisel, F., Petillon, M.O., Webb, I., Mathiot, C. & Moreau, P. (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. Journal of Clinical Oncology, 28, 4621-4629.
54. Holland, J., Trenkner, D.A., Wasserman, T.H. & Fineberg, B. (1992) Plasmacytoma. Treatment results and conversion to myeloma. Cancer, 69, 1513-1517.
55. Jakubowiak, A.J., Dytfeld, D., Griffith, K.A., Lebovic, D., Vesole, D.H., Jagannath, S., Al-Zoubi, A., Anderson, T., Nordgren, B., Detweiler-Short, K., Stockerl-Goldstein, K., Ahmed, A., Jobkar, T., Durecki, D.E., McDonnell, K., Mietzel, M., Couriel, D., Kaminski, M. & Vij, R. (2012) A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 120, 1801-1809.
56. Kapoor, P., Rajkumar, S.V., Dispenzieri, A., Gertz, M.A., Lacy, M.Q., Dingli, D., Mikhael, J.R., Roy, V., Kyle, R.A., Greipp, P.R., Kumar, S. & Mandrekar, S.J. (2011) Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia, 25, 689-696.
57. Keats, J.J., Chesi, M., Egan, J.B., Garbitt, V.M., Palmer, S.E., Braggio, E., Van Wier, S., Blackburn, P.R., Baker, A.S., Dispenzieri, A., Kumar, S., Rajkumar, S.V., Carpten, J.D., Barrett, M., Fonseca, R., Stewart, A.K. & Bergsagel, P.L. (2012) Clonal competition with alternating dominance in multiple myeloma. Blood, 120, 1067-1076.
58. Kilciksiz, S., Karakoyun-Celik, O., Agaoglu, F.Y. & Haydaroglu, A. (2012) A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Scientific World Journal, 2012, 895765.
59. Kumar, A., Kharfan-Dabaja, M.A., Glasmacher, A. & Djulbegovic, B. (2009) Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. Journal of the National Cancer Institute, 101, 100-106.
60. Kumar, S., Flinn, I., Richardson, P.G., Hari, P., Callander, N., Noga, S.J., Stewart, A.K., Turturro, F., Rifkin, R., Wolf, J., Estevam, J., Mulligan, G., Shi, H., Webb, I.J. & Rajkumar, S.V. (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood, 119, 4375-4382.
61. Lee, W., Jiang, Z., Liu, J., Haverty, P.M., Guan, Y., Stinson, J., Yue, P., Zhang, Y., Pant, K.P., Bhatt, D., Ha, C., Johnson, S., Kennemer, M.I., Mohan, S., Nazarenko, I., Watanabe, C., Sparks, A.B., Shames, D.S., Gentleman, R., de Sauvage, F.J., Stern, H., Pandita, A., Ballinger, D.G., Drmanac, R., Modrusan, Z., Seshagiri, S. & Zhang, Z. (2010) The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature, 465, 473-477.
62. Leleu, X., Fouquet, G., Hebraud, B., Roussel, M., Caillot, D., Chretien, M.L., Arnulf, B., Szalat, R., Garderet, L., Benajiba, L., Pegourie, B., Regny, C., Royer, B., Caulier, A., Stoppa, A.M., Garciaz, S., Touzeau, C., Chaleteix, C., Fermand, J.P., Loiseau, H.A., Facon, T., Attal, M. & Moreau, P. (2013) Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. Leukemia, 27, 2242-2244.
63. Ley, T.J., Mardis, E.R., Ding, L., Fulton, B., McLellan, M.D., Chen, K., Dooling, D., Dunford-Shore, B.H., McGrath, S., Hickenbotham, M., Cook, L., Abbott, R., Larson, D.E., Koboldt, D.C., Pohl, C., Smith, S., Hawkins, A., Abbott, S., Locke, D., Hillier, L.W., Miner, T., Fulton, L., Magrini, V., Wylie, T., Glasscock, J., Conyers, J., Sander, N., Shi, X., Osborne, J.R., Minx, P., Gordon, D., Chinwalla, A., Zhao, Y., Ries, R.E., Payton, J.E., Westervelt, P., Tomasson, M.H., Watson, M., Baty, J., Ivanovich, J., Heath, S., Shannon, W.D., Nagarajan, R., Walter, M.J., Link, D.C., Graubert, T.A., DiPersio, J.F. & Wilson, R.K. (2008) DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature, 456, 66-72.
64. Lode, L., Eveillard, M., Trichet, V., Soussi, T., Wuilleme, S., Richebourg, S., Magrangeas, F., Ifrah, N., Campion, L., Traulle, C., Guilhot, F., Caillot, D., Marit, G., Mathiot, C., Facon, T., Attal, M., Harousseau, J.L., Moreau, P., Minvielle, S. & Avet-Loiseau, H. (2010) Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica, 95, 1973-1976.
65. Lohr, J.G., Stojanov, P., Carter, L.S., Cruz-Gordillo, P., Lawrence, M.S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., Cibulskis, K., McKenna, A., Chapman, M.A., Straussman, R., Levy, J., Perkins, L.M., Keats, J.J., Schumacher, S.E., Rosenberg, M., Getz, G. & Golub, T.R., The Multiple Myeloma Research Consortium (2014) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell, 25, 91-101
66. Lopez-Corral, L., Mateos, M.V., Corchete, L.A., Sarasquete, M.E., de la Rubia, J., de Arriba, F., Lahuerta, J.J., Garcia-Sanz, R., San Miguel, J.F. & Gutierrez, N.C. (2012) Genomic analysis of high-risk smoldering multiple myeloma. Haematologica, 97, 1439-1443.
67. Ludwig, H., Adam, Z., Tothova, E., Hajek, R., Labar, B., Egyed, M., Spicka, I., Gisslinger, H., Drach, J., Kuhn, I., Hinke, A. & Zojer, N. (2010) Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica, 95, 1548-1554.
68. Magrangeas, F., Avet-Loiseau, H., Gouraud, W., Lode, L., Decaux, O., Godmer, P., Garderet, L., Voillat, L., Facon, T., Stoppa, A.M., Marit, G., Hulin, C., Casassus, P., Tiab, M., Voog, E., Randriamalala, E., Anderson, K.C., Moreau, P., Munshi, N.C. & Minvielle, S. (2013) Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia, 27, 473-481.
69. Mateos, M.V., Hernandez, M.T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L.L., Rosinol, L., Paiva, B., Palomera, L., Bargay, J., Oriol, A., Prosper, F., Lopez, J., Olavarria, E., Quintana, N., Garcia, J.L., Blade, J., Lahuerta, J.J. & San Miguel, J.F. (2013) Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. New England Journal of Medicine, 369, 438-447.
70. Matsui, W., Huff, C.A., Wang, Q., Malehorn, M.T., Barber, J., Tanhehco, Y., Smith, B.D., Civin, C.I. & Jones, R.J. (2004) Characterization of clonogenic multiple myeloma cells. Blood, 103, 2332-2336.
71. Matsui, W., Wang, Q., Barber, J.P., Brennan, S., Smith, B.D., Borrello, I., McNiece, I., Lin, L., Ambinder, R.F., Peacock, C., Watkins, D.N., Huff, C.A. & Jones, R.J. (2008) Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Research, 68, 190-197.
72. McCarthy, P.L., Owzar, K., Hofmeister, C.C., Hurd, D.D., Hassoun, H., Richardson, P.G., Giralt, S., Stadtmauer, E.A., Weisdorf, D.J., Vij, R., Moreb, J.S., Callander, N.S., Van Besien, K., Gentile, T., Isola, L., Maziarz, R.T., Gabriel, D.A., Bashey, A., Landau, H., Martin, T., Qazilbash, M.H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M.C., Horowitz, M.M., Shea, T.C., Devine, S.M., Anderson, K.C. & Linker, C. (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 366, 1770-1781.
73. Melchor, L., Brioli, A., Wardell, C.P., Murison, A., Potter, N.E., Kaiser, M.F., Fryer, R.A., Johnson, D.C., Begum, D.B., Hulkki Wilson, S., Vijayaraghavan, G., Titley, I., Cavo, M., Davies, F.E., Walker, B.A. & Morgan, G.J. (2014) Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia, doi: 10.1038/leu.2014.13.
74. Moreau, P., Avet-Loiseau, H., Facon, T., Attal, M., Tiab, M., Hulin, C., Doyen, C., Garderet, L., Randriamalala, E., Araujo, C., Lepeu, G., Marit, G., Caillot, D., Escoffre, M., Lioure, B., Benboubker, L., Pegourie, B., Kolb, B., Stoppa, A.M., Fuzibet, J.G., Decaux, O., Dib, M., Berthou, C., Chaleteix, C., Sebban, C., Traulle, C., Fontan, J., Wetterwald, M., Lenain, P., Mathiot, C. & Harousseau, J.L. (2011) Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood, 118, 5752-5758; quiz 5982.
75. Morgan, G.J., Davies, F.E., Gregory, W.M., Cocks, K., Bell, S.E., Szubert, A.J., Navarro-Coy, N., Drayson, M.T., Owen, R.G., Feyler, S., Ashcroft, A.J., Ross, F., Byrne, J., Roddie, H., Rudin, C., Cook, G., Jackson, G.H. & Child, J.A. (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet, 376, 1989-1999.
76. Morgan, G.J., Davies, F.E., Gregory, W.M., Russell, N.H., Bell, S.E., Szubert, A.J., Navarro Coy, N., Cook, G., Feyler, S., Byrne, J.L., Roddie, H., Rudin, C., Drayson, M.T., Owen, R.G., Ross, F.M., Jackson, G.H. & Child, J.A. (2011) Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood, 118, 1231-1238.
77. Morgan, G.J., Walker, B.A. & Davies, F.E. (2012a) The genetic architecture of multiple myeloma. Nature Reviews Cancer, 12, 335-348.
78. Morgan, G.J., Davies, F.E., Gregory, W.M., Bell, S.E., Szubert, A.J., Navarro Coy, N., Cook, G., Feyler, S., Johnson, P.R.E., Rudin, C., Drayson, M.T., Owen, R.G., Ross, F.M., Russell, N.H., Jackson, G.H. & Child, J.A. (2012b) Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica, 97, 442-450.
79. Morgan, G.J., Gregory, W.M., Davies, F.E., Bell, S.E., Szubert, A.J., Brown, J.M., Coy, N.N., Cook, G., Russell, N.H., Rudin, C., Roddie, H., Drayson, M.T., Owen, R.G., Ross, F.M., Jackson, G.H. & Child, J.A. (2012c) The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood, 119, 7-15.
80. Mukherjee, S., Raje, N., Schoonmaker, J.A., Liu, J.C., Hideshima, T., Wein, M.N., Jones, D.C., Vallet, S., Bouxsein, M.L., Pozzi, S., Chhetri, S., Seo, Y.D., Aronson, J.P., Patel, C., Fulciniti, M., Purton, L.E., Glimcher, L.H., Lian, J.B., Stein, G., Anderson, K.C. & Scadden, D.T. (2008) Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. The Journal of Clinical Investigation, 118, 491-504.
81. Mullighan, C.G., Phillips, L.A., Su, X., Ma, J., Miller, C.B., Shurtleff, S.A. & Downing, J.R. (2008) Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science, 322, 1377-1380.
82. Neri, A., Murphy, J.P., Cro, L., Ferrero, D., Tarella, C., Baldini, L. & Dalla-Favera, R. (1989) Ras oncogene mutation in multiple myeloma. Journal of Experimental Medicine, 170, 1715-1725.
83. Nik-Zainal, S., Van Loo, P., Wedge David, C., Alexandrov Ludmil, B., Greenman Christopher, D., Lau King, W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., Shlien, A., Cooke Susanna, L., Hinton, J., Menzies, A., Stebbings Lucy, A., Leroy, C., Jia, M., Rance, R., Mudie Laura, J., Gamble Stephen, J., Stephens Philip, J., McLaren, S., Tarpey Patrick, S., Papaemmanuil, E., Davies Helen, R., Varela, I., McBride David, J., Bignell Graham, R., Leung, K., Butler Adam, P., Teague Jon, W., Martin, S., Jönsson, G., Mariani, O., Boyault, S., Miron, P., Fatima, A., Langerød, A., Aparicio Samuel, A.J.R., Tutt, A., Sieuwerts Anieta, M., Borg, Å., Thomas, G., Salomon Anne, V., Richardson Andrea, L., Børresen-Dale, A.-L., Futreal, P.A., Stratton Michael, R. & Campbell Peter, J. (2012) The life history of 21 breast cancers. Cell, 149, 994-1007.
84. Nowell, P.C. (1976) The clonal evolution of tumor cell populations. Science, 194, 23-28.
85. Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., Benevolo, G., Callea, V., Baldini, L., Morabito, F., Grasso, M., Leonardi, G., Rizzo, M., Falcone, A.P., Gottardi, D., Montefusco, V., Musto, P., Petrucci, M.T., Ciccone, G. & Boccadoro, M. (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. Journal of Clinical Oncology, 28, 5101-5109.
86. Palumbo, A., Hajek, R., Delforge, M., Kropff, M., Petrucci, M.T., Catalano, J., Gisslinger, H., Wiktor-Jedrzejczak, W., Zodelava, M., Weisel, K., Cascavilla, N., Iosava, G., Cavo, M., Kloczko, J., Blade, J., Beksac, M., Spicka, I., Plesner, T., Radke, J., Langer, C., Ben Yehuda, D., Corso, A., Herbein, L., Yu, Z., Mei, J., Jacques, C. & Dimopoulos, M.A. (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. New England Journal of Medicine, 366, 1759-1769.
87. Papanikolaou, X., Barlogie, B. & Usmani, S.Z. (2011) Therapy-related myeloid malignancies in myeloma. Mediterranean Journal of Hematology and Infectious Diseases, 3, e2011047.
88. Pineda-Roman, M., Bolejack, V., Arzoumanian, V., Anaissie, E., van Rhee, F., Zangari, M., Walker, R., Hollmig, K., Shaughnessy, J.D. Jr, Epstein, J., Krishna, S., Crowley, J. & Barlogie, B. (2007) Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. British Journal of Haematology, 136, 393-399.
89. Rajkumar, S.V., Jacobus, S., Callander, N.S., Fonseca, R., Vesole, D.H., Williams, M.E., Abonour, R., Siegel, D.S., Katz, M. & Greipp, P.R. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncology, 11, 29-37.
90. Richardson, P.G., Weller, E., Lonial, S., Jakubowiak, A.J., Jagannath, S., Raje, N.S., Avigan, D.E., Xie, W., Ghobrial, I.M., Schlossman, R.L., Mazumder, A., Munshi, N.C., Vesole, D.H., Joyce, R., Kaufman, J.L., Doss, D., Warren, D.L., Lunde, L.E., Kaster, S., Delaney, C., Hideshima, T., Mitsiades, C.S., Knight, R., Esseltine, D.L. & Anderson, K.C. (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood, 116, 679-686.
91. Roussel, M., Robillard, N., Moreau, P., Benboubker, L., Hulin, C., Marit, G., Leleu, X., Pegourie, B., Fruchart, C., Caillot, D., Stoppa, A.-M., Facon, T., Wuilleme, S., Avet-Loiseau, H. & Attal, M. (2011) Bortezomib, Lenalidomide, and Dexamethasone (VRD) consolidation and lenalidomide maintenance in frontline multiple myeloma patients: updated results of the IFM 2008 Phase II VRD intensive program. Blood, 118, 1872.
92. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. & Richardson, P.G. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906-917.
93. San Miguel, J., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., Alegre, A., Chen, C., Cavo, M., Garderet, L., Ivanova, V., Martinez-Lopez, J., Belch, A., Palumbo, A., Schey, S., Sonneveld, P., Yu, X., Sternas, L., Jacques, C., Zaki, M. & Dimopoulos, M. (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncology, 14, 1055-1066.
94. Santarpia, L., Lippman, S.M. & El-Naggar, A.K. (2012) Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 16, 103-119.
95. Shaughnessy, J.D. Jr, Qu, P., Usmani, S., Heuck, C.J., Zhang, Q., Zhou, Y., Tian, E., Hanamura, I., van Rhee, F., Anaissie, E., Epstein, J., Nair, B., Stephens, O., Williams, R., Waheed, S., Alsayed, Y., Crowley, J. & Barlogie, B. (2011) Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood, 118, 3512-3524.
96. Siegmund, K.D., Marjoram, P., Woo, Y.J., Tavare, S. & Shibata, D. (2009) Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America, 106, 4828-4833.
97. Sonneveld, P., Schmidt-Wolf, I.G., van der Holt, B., El Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I.W., Weisel, K.C., Wittebol, S., Bos, G.M., Stevens-Kroef, M., Scheid, C., Pfreundschuh, M., Hose, D., Jauch, A., van der Velde, H., Raymakers, R., Schaafsma, M.R., Kersten, M.J., van Marwijk-Kooy, M., Duehrsen, U., Lindemann, W., Wijermans, P.W., Lokhorst, H.M. & Goldschmidt, H.M. (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. Journal of Clinical Oncology, 30, 2946-2955.
98. Sonneveld, P., Scheid, C., Van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I.W., Weisel, K., Wittebol, S., Bos, G.M.J., Stevens, M., Schmidt-Wolf, I.G.H., Pfreundschuh, M., Hose, D., Jauch, A., van de Velde, H., Raymakers, R., Schaafsma, M.R., Kersten, M.J., Van Marwijk Kooy, M., Duehrsen, U., Lindemann, H.W., Wijermans, P.W., Lokhorst, H. & Goldschmidt, H. (2013) Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma:extended follow-up of the HOVON-65/GMMG-HD4 Trial. Blood, 122, 404.
99. Spencer, A., Prince, H.M., Roberts, A.W., Prosser, I.W., Bradstock, K.F., Coyle, L., Gill, D.S., Horvath, N., Reynolds, J. & Kennedy, N. (2009) Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. Journal of Clinical Oncology, 27, 1788-1793.
100. The International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology, 121, 749-757.
101. Usmani, S.Z., Sexton, R., Hoering, A., Heuck, C.J., Nair, B., Waheed, S., Al Sayed, Y., Chauhan, N., Ahmad, N., Atrash, S., Petty, N., van Rhee, F., Crowley, J. & Barlogie, B. (2012) Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood, 120, 1597-1600.
102. van de Velde, H.J.K., Liu, X., Chen, G., Cakana, A., Deraedt, W. & Bayssas, M. (2007) Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica, 92, 1399-1406.
103. Vij, R., Siegel, D.S., Jagannath, S., Jakubowiak, A.J., Stewart, A.K., McDonagh, K., Bahlis, N., Belch, A., Kunkel, L.A., Wear, S., Wong, A.F. & Wang, M. (2012) An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. British Journal of Haematology, 158, 739-748.
104. Walker, B.A., Leone, P.E., Chiecchio, L., Dickens, N.J., Jenner, M.W., Boyd, K.D., Johnson, D.C., Gonzalez, D., Dagrada, G.P., Protheroe, R.K., Konn, Z.J., Stockley, D.M., Gregory, W.M., Davies, F.E., Ross, F.M. & Morgan, G.J. (2010) A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood, 116, e56-e65.
105. Walker, B.A., Wardell, C.P., Chiecchio, L., Smith, E.M., Boyd, K.D., Neri, A., Davies, F.E., Ross, F.M. & Morgan, G.J. (2011) Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood, 117, 553-562.
106. Walker, B.A., Wardell, C.P., Melchor, L., Hulkki, S., Potter, N.E., Johnson, D.C., Fenwick, K., Kozarewa, I., Gonzalez, D., Lord, C.J., Ashworth, A., Davies, F.E. & Morgan, G.J. (2012) Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood, 120, 1077-1086.
107. Walker, B.A., Wardell, C.P., Melchor, L., Brioli, A., Johnson, D.C., Kaiser, M.F., Mirabella, F., Lopez-Corral, L., Humphray, S., Murray, L., Ross, M., Bentley, D., Gutierrez, N.C., Garcia-Sanz, R., San Miguel, J., Davies, F.E., Gonzalez, D. & Morgan, G.J. (2014) Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia, 28, 384-390.
108. Yaccoby, S. & Epstein, J. (1999) The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood, 94, 3576-3582.
109. Yaccoby, S., Barlogie, B. & Epstein, J. (1998) Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood, 92, 2908-2913.
110. Yaccoby, S., Pennisi, A., Li, X., Dillon, S.R., Zhan, F., Barlogie, B. & Shaughnessy, J.D. Jr (2008) Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia, 22, 406-413.
111. Zingone, A., Cultraro, C.M., Shin, D.M., Bean, C.M., Morse, H.C. III, Janz, S. & Kuehl, W.M. (2010) Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms. Leukemia, 24, 1171-1178.